Tvardi Therapeutics Inc
F:69C
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Tvardi Therapeutics Inc (69C) under the Base Case is 5.24 EUR per share.
Compared with the current market price of 0.8 EUR, the stock appears
Undervalued by 85% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Tvardi Therapeutics Does
Cara Therapeutics is a biopharmaceutical company that develops prescription medicines for severe itch and pain. Its work has centered on drug candidates that act on the body’s opioid receptors, especially the kappa opioid receptor, which it studies as a way to relieve symptoms without relying on traditional painkillers. In simple terms, it is a drug developer, not a drug distributor or clinic operator.
- Headquarters
- United States of America US
- Employees
- 12
- IPO date
- Jan 31, 2014
Balance Sheet
Continue 69C Research
Decided on Tvardi Therapeutics? Get an email when 69C reaches the price you’d buy at. Free with an account.
Other Tvardi Therapeutics listings
What is the Intrinsic Value of one 69C stock?
The intrinsic value for
Tvardi Therapeutics Inc (69C) under the Base Case is 5.24 EUR.
Is 69C stock undervalued or overvalued?
Compared with the current market price of 0.8 EUR, the stock appears Undervalued by 85% .